CAS 88-12-0, NVP/N-vinylpyrrolidone Pharma Grade API, molecular formula C₆H₉NO, is a low-color liquid vinyl monomer supplied under the designation NVP-PG. The material functions as a controlled-purity polymerizable building block for pharmaceutical-grade povidone, crospovidone, and vinylpyrrolidone-vinyl acetate copolymers rather than as a directly compressible tablet filler or injectable active. The designation NVP-PG distinguishes the low-water, low-aldehyde, inhibitor-controlled material from technical-grade reactive diluent streams. Typical packaging consists of 200 L nitrogen-blanketed HDPE drums or 1000 L stainless steel intermediate bulk containers fitted with dip-tube transfer to limit atmospheric oxygen ingress. Molecular weight is 111.14 g/mol, density is 1.043–1.045 g/cm³ at 25 °C, and freezing point is 13–14 °C; storage above 15 °C prevents line crystallization in unheated transfer areas. The liquid monomer is water-miscible and hydrolytically stable under neutral pH storage, but it must be segregated from strong acids, free-radical initiators, and transition-metal salts.

How Does Pharma Grade NVP Differ from Technical-Grade Reactive Diluent Supply?

Pharma grade NVP differs from technical-grade material primarily in color, water, peroxide, aldehyde, non-volatile residue, and stabilizer content. Technical-grade NVP is often sold for UV-curing and coatings applications and may carry inhibitor packages of 25–50 ppm; these higher inhibitor loads can retard pharmaceutical polymerizations and leave odorous amine residues. Pharma grade release uses a narrow window: purity by GC ≥99.5%, water by Karl Fischer ≤0.1% w/w, APHA color ≤10, peroxide as H₂O₂ ≤5 ppm, non-volatile residue ≤0.01% w/w, and inhibitor content at 10–20 ppm. The stabilizer chemistry is selected for compatibility with free-radical solution polymerization at 0.1–0.5 mol% initiator loading. Compared with vinyl acetate, NVP introduces a pyrrolidone ring that yields non-ionic and water-soluble polymers without pendant ester hydrolysis; compared with acrylic acid, NVP avoids anionic charge density and pH-dependent viscosity. Compared with N-methyl-2-pyrrolidone, NVP contains a vinyl group that permits incorporation into polymer backbones rather than functioning solely as a solvent. Published lot-to-lot variance data across all global producers is limited; therefore, a reference polymerization test with fixed initiator and temperature is used at receiving inspection to verify K-value reproducibility.

For tablet, capsule, granule, oral solution, and injectable applications, NVP is not added directly as neat monomer to the finished drug product. The derived polymers—linear povidone K12, K17, K29/32, K90, crosslinked crospovidone Type A/B, and copovidone—are manufactured from pharma grade NVP and subsequently formulated at defined use levels. A representative release comparison and a dosage-form function matrix are shown below; values should be confirmed against the active supplier certificate and current monograph because published data for this specific configuration is limited.

Parameter	Pharma grade release range	Technical grade typical	Test methodology
Appearance	Clear, free of visible crystals	Clear	Visual inspection
Purity, GC area%	≥99.5	98.0–99.0	GC-FID, internal standard
Water, w/w%	≤0.1	≤0.3	Karl Fischer, Ph. Eur. 2.5.12 / USP <921>
APHA color	≤10	≤25	ASTM D1209-21
Peroxide as H₂O₂, ppm	≤5	≤15	Iodometric titration
Inhibitor content, ppm	10–20	25–50	HPLC-UV
Non-volatile residue, w/w%	≤0.01	≤0.05	ASTM D1353-13
Density at 25 °C, g/cm³	1.043–1.045	1.043	ASTM D4052-22
Freezing point, °C	13–14	13–14	DSC
Viscosity at 25 °C, mPa·s	2.0–2.5	2.0–2.5	ASTM D445-23 / ISO 3104:2023

Material outside the pharma grade water, aldehyde, or peroxide window is not reworked by simple addition of fresh inhibitor; it is returned or reprocessed by fractional distillation under reduced pressure at 10–20 mbar and 85–95 °C column top temperature, followed by stabilizer re-addition in a nitrogen-blanketed receiver. Aliquots for release testing are taken from the middle of each drum with a stainless steel thief under positive nitrogen pressure. The retention sample requires a sealed glass ampoule under nitrogen and is stored at 2–8 °C for 24 months. The polymerization activity test uses a standardized thermal ramp from 60 °C to 80 °C at 0.5 °C/min with 0.2 mol% azobisisobutyronitrile and reports time to 10% conversion by FTIR disappearance of the vinyl band at 1628–1632 cm⁻¹.

Stabilizer Selection and Storage Envelope

NVP is intrinsically prone to radical polymerization; therefore, the pharma grade liquid is stabilized with a controlled amount of free-radical inhibitor. Storage under nitrogen or argon with headspace oxygen below 5 vol% preserves inhibitor activity. The recommended storage range is 15–30 °C; temperatures below 13 °C cause crystallization, and reheating is performed gradually to 40 °C with recirculation because localized hot spots can generate peroxides. Prolonged storage above 30 °C accelerates dimer and oligomer formation; drums opened for partial use should be re-blanketed and tested monthly for peroxide if stored beyond 30 days. Transfer equipment in production-scale polymer plants is normally constructed of 316L stainless steel or polyethylene-lined carbon steel with a nitrogen sweep of 0.2–0.5 bar. Copper and iron surfaces are incompatible for extended residence because transition metals catalyze vinyl polymerization. The material should also be protected from strong oxidizing agents and strong acids; contact with these substances can initiate exothermic polymerization and generate heat beyond the cooling capacity of a 5 m³ glass-lined reactor.

During wet granulation of poorly compressible or high-dose APIs, linear povidone produced from pharma grade NVP is dissolved in water or hydroalcoholic granulation fluid at 1–5% w/w dry binder relative to granule mass. A 10% w/w aqueous solution of povidone K29/32 exhibits viscosity of 5.5–8.5 mPa·s at 25 °C; this viscosity window controls wet mass consistency, impeller power draw, and granule end-point on a high-shear granulator operating at impeller speeds of 200–400 rpm and chopper speeds of 1000–3000 rpm. If the monomer source contains elevated aldehyde or color bodies above the pharma grade limit, the resulting povidone can yellow and exhibit broader K-value distribution, which shifts tablet hardness and disintegration. Crospovidone synthesized from pharma grade NVP is used as a tablet and capsule disintegrant at 2–5% w/w; its crosslinked morphology provides wicking and swelling without forming a gel film. Tablets are tested for disintegration per USP <701> and hardness on a constant-speed tablet hardness tester; formulations with highly swellable crospovidone may require reduced compression force below 15 kN to avoid overcompression and delayed disintegration. Hard gelatin capsules use the same granules; fill weight variability is minimized when moisture content is 2–4% before encapsulation.

When Peroxide and Aldehyde Levels Constrain Injectable Polymer Synthesis

Injectable-grade povidone K12 and K17 are synthesized from monomer lots in which peroxide and aldehyde levels are restricted because these impurities determine oxidative stability and color after free-radical solution polymerization. Peroxide content above 5 ppm in the monomer can initiate premature oligomer formation during storage and broaden molecular weight distribution; for injectable solubilizers and lyoprotectants used at 0.1–10% w/v, molecular weight distribution influences renal clearance and solution viscosity. Polymerization is performed in glass-lined or 316L stainless steel reactors under nitrogen using hydrogen peroxide or azo initiators at 60–90 °C. Monomer feed rate and initiator half-life are matched so that residual NVP in the final povidone remains below the pharmacopoeial limit, which is typically a low parts-per-million range aligned with the current Ph. Eur. povidone monograph. The monomer is not rendered sterile or endotoxin-free by distillation alone; downstream sterilization of the bulk polymer solution, commonly by 0.2 µm filtration and steam sterilization at 121 °C for 15 min, is required for injectable processing. Water used in polymerization complies with compendial water for injection quality.

In oral solutions, povidone K12 or K17 synthesized from pharma grade NVP functions as a non-ionic stabilizer and viscosity modifier at 0.5–5% w/v; because the pyrrolidone ring remains uncharged, viscosity is less sensitive to pH and electrolyte changes than carbomer or alginate systems. Copovidone, produced from NVP and vinyl acetate, is used in hot-melt extrusion and solvent-based film coating with a vinyl acetate content of 30–40% w/w; the NVP fraction lowers melt viscosity and improves drug-polymer miscibility. In twin-screw hot-melt extrusion, copovidone is processed at barrel temperatures from 120–160 °C with an L/D ratio of 40:1; residual monomer should remain below specification because high-shear thermal processing can strip inhibitor and generate reactive species. These differences distinguish NVP-derived materials from cellulosic binders, which are non-synthetic and require different granulation endpoint control, and from methacrylate-based systems, which are ionic and pH-dependent.

Dosage form	Derived polymer	Typical use level	Critical NVP control parameter
Wet granulation tablet	Povidone K29/32	1–5% w/w dry binder	K-value, residual NVP, water
Tablet/capsule disintegrant	Crospovidone Type A/B	2–5% w/w	Peroxide, crosslinker residue
Injectable solution/lyophilized product	Povidone K12/K17	0.1–10% w/v	Endotoxin, residual monomer, molecular weight
Oral solution/suspension	Povidone K12/K17	0.5–5% w/v	Aldehydes, color
Hot-melt extrusion tablet/capsule	Copovidone	20–40% w/w of matrix	Vinyl acetate ratio, residual monomer, glass transition

Release Criteria and Pharmacopoeial Alignment for Downstream Povidone

Because NVP itself is not a dosage form ingredient, its specification is justified through the finished polymer monograph and through residual monomer limits applied to povidone and crospovidone. The current Ph. Eur. povidone monograph limits residual NVP and water, and the USP/NF povidone monograph sets K-value and water requirements. Release criteria for elemental impurities in pharma grade NVP are aligned with ICH Q3D Option 1; typical values for Class 1 and 2A elements are below the oral and parenteral permitted daily exposure limits, but the monomer supplier’s declaration should be confirmed for each lot. Residual solvents from synthesis, if any, are evaluated under ICH Q3C. The polymer producer is responsible for verifying that the monomer lot does not contribute mutagenic nitrosamines above the acceptable intake defined by the current regional guidance; peroxide and amine stabilizers are selected to minimize nitrosating conditions.

Batch acceptance in a pharmaceutical polymer plant includes a small-scale reference polymerization using 0.2 mol% azobisisobutyronitrile at 70 °C in isopropanol/water and comparison of the resulting K-value against the qualified reference lot. A lot failing to reproduce K-value within ±1.5 K units is not used for commercial povidone production. This polymerization test is more discriminating for trace aldehyde and inhibitor variability than bulk purity analysis alone. For injectable projects, an additional endotoxin screen and subvisible particle count after 0.2 µm filtration are performed on the polymer prepared from the monomer lot. Published data for every supplier configuration is limited; therefore, the receiving laboratory establishes internal acceptance limits from the first three commercial lots and reviews them under change control when monomer source or inhibitor package changes.